Remove Genetics Remove Pharmacy Remove Scientist
article thumbnail

Cell and gene therapies: why advanced medicines call for specialised logistics

Pharmaceutical Technology

Genetic mutations, both germline and acquired, are behind a large proportion of the most debilitating and sometimes life-threatening human diseases. But scientists have struggled to find effective treatments for many of these diseases since the dawn of modern medicine.

article thumbnail

Pharmacognosy and Drug Patents: Unveiling Nature’s Medicinal Treasures

Drug Patent Watch

The Essence of Pharmacognosy: Nature’s Pharmacy Unveiled Imagine walking through a lush rainforest, surrounded by countless plant species. Scientists in this field analyze the chemical compounds in plants, animals, and microorganisms to discover potential new drugs.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Scientists found out genes involved in a compound in lichens with antiviral activity

Scienmag

An international study led by researchers from the Faculty of Pharmacy at the Complutense University of Madrid has identified a series of biosynthetic genes involved in the production of usnic acid in lichen, a compound showing antiviral, antioxidant, neuroprotective, antibacterial and anticancer activity.

Gene 52
article thumbnail

Addressing Healthcare Challenges and Innovations with Pepperdine University’s Dr. Gary Mangiofico

XTalks

The disjointed interactions among insurers, managed care providers, pharmacy benefit managers and clinicians hinder efficient population health management and disease prevention. . “The area of simplifying payment systems is perhaps one of the areas in most need of reform, thus innovation,” he says.

DNA 59
article thumbnail

REGN-COV2 Independent Data Monitoring Committee Recommends Holding Enrollment in Hospitalized Patients with High Oxygen Requirements and Continuing Enrollment in Patients with Low or No Oxygen Requirements

The Pharma Data

To develop REGN-COV2, Regeneron scientists evaluated thousands of fully-human antibodies produced by the company’s VelocImmune ® mice, which have been genetically modified to have a human immune system, as well as antibodies identified from humans who have recovered from COVID-19.

article thumbnail

New England Journal of Medicine Publishes Positive Initial Regeneron Antibody Cocktail Results in Non-hospitalized Patients with COVID-19

The Pharma Data

To develop this novel medicine, Regeneron scientists evaluated thousands of fully-human antibodies produced by the company’s VelocImmune ® mice, which have been genetically modified to have a human immune system, as well as antibodies identified from humans who have recovered from COVID-19.

article thumbnail

Regeneron’s COVID-19 Outpatient Trial Prospectively Demonstrates that REGN-COV2 Antibody Cocktail Significantly Reduced Virus Levels and Need for Further Medical Attention

The Pharma Data

To develop REGN-COV2, Regeneron scientists evaluated thousands of fully-human antibodies produced by the company’s VelocImmune ® mice, which have been genetically modified to have a human immune system, as well as antibodies identified from humans who have recovered from COVID-19.